The recombinant shingles vaccine is associated with lower risk of dementia

5Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.
Get full text

Abstract

There is emerging evidence that the live herpes zoster (shingles) vaccine might protect against dementia. However, the existing data are limited and refer only to the live vaccine, which is now discontinued in the United States and many other countries in favor of a recombinant vaccine. Whether the recombinant shingles vaccine protects against dementia remains unknown. Here we used a natural experiment opportunity created by the rapid transition from the use of live to the use of recombinant vaccines to compare the risk of dementia between vaccine types. We show that the recombinant vaccine is associated with a significantly lower risk of dementia in the 6 years post-vaccination. Specifically, receiving the recombinant vaccine is associated with a 17% increase in diagnosis-free time, translating into 164 additional days lived without a diagnosis of dementia in those subsequently affected. The recombinant shingles vaccine was also associated with lower risks of dementia than were two other vaccines commonly used in older people: influenza and tetanus–diphtheria–pertussis vaccines. The effect was robust across multiple secondary analyses, and was present in both men and women but was greater in women. These findings should stimulate studies investigating the mechanisms underpinning the protection and could facilitate the design of a large-scale randomized control trial to confirm the possible additional benefit of the recombinant shingles vaccine.

References Powered by Scopus

Matching methods for causal inference: A review and a look forward

3726Citations
N/AReaders
Get full text

Causal inference without balance checking: Coarsened exact matching

2116Citations
N/AReaders
Get full text

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

1409Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antibodies in neurological diseases: Established, emerging, explorative

3Citations
N/AReaders
Get full text

Infectious Disease as a Modifiable Risk Factor for Dementia: A Narrative Review

2Citations
N/AReaders
Get full text

Recombinant zoster vaccine and the risk of dementia

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Taquet, M., Dercon, Q., Todd, J. A., & Harrison, P. J. (2024). The recombinant shingles vaccine is associated with lower risk of dementia. Nature Medicine. https://doi.org/10.1038/s41591-024-03201-5

Readers' Seniority

Tooltip

Researcher 10

43%

PhD / Post grad / Masters / Doc 7

30%

Professor / Associate Prof. 3

13%

Lecturer / Post doc 3

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

33%

Agricultural and Biological Sciences 6

25%

Social Sciences 6

25%

Immunology and Microbiology 4

17%

Article Metrics

Tooltip
Mentions
Blog Mentions: 2
News Mentions: 270
References: 2
Social Media
Shares, Likes & Comments: 238

Save time finding and organizing research with Mendeley

Sign up for free